A PHD inhibitor prevents changes in the phosphoproteome and capillary rarefaction by CsA: treatment option for CKD?

Schley G, Goppelt-Strübe M (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Kidney International Nature Publishing Group: Open Access Hybrid Model Option A

Book Volume: 102

Pages Range: 686-688

Journal Issue: 4

DOI: 10.1016/j.kint.2022.06.020

Abstract

Labes et al. analyze the phosphoproteome in a mouse model of chronic cyclosporine A nephrotoxicity and detect significant changes in the angiogenic pathway. Furthermore, they observe reduced hemoglobin levels and capillary rarefaction in the kidney. The authors show that coadministration of the hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat almost completely prevents changes of the phosphoproteome and capillary rarefaction, suggesting that prolyl hydroxylase domain enzyme inhibitors may preserve microvasculature of the kidney, which is commonly impaired in chronic kidney disease.

Authors with CRIS profile

Gunnar Schley Department of Medicine 4 – Nephrology and Hypertension Margarete Goppelt-Strübe Department of Medicine 4 – Nephrology and Hypertension

How to cite

APA:

Schley, G., & Goppelt-Strübe, M. (2022). A PHD inhibitor prevents changes in the phosphoproteome and capillary rarefaction by CsA: treatment option for CKD? Kidney International, 102(4), 686-688. https://dx.doi.org/10.1016/j.kint.2022.06.020

MLA:

Schley, Gunnar, and Margarete Goppelt-Strübe. "A PHD inhibitor prevents changes in the phosphoproteome and capillary rarefaction by CsA: treatment option for CKD?" Kidney International 102.4 (2022): 686-688.

BibTeX: Download